App-Quantinova.ai

MicroRNA Sequencing Highlights Regulatory Networks Upstream of Osteopontin and B-type Natriuretic Peptide in Acute Coronary Sydrome

Elizabeth Grass - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Acute Coronary Syndromes

N/A

Dyslipidemia May Represent a Cyclic GMP Deficiency State: Insights From a General Community

Christopher G. Scott - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Metabolic syndrome

N/A

Relationship of Biomarkers: Clinical Depression or Heart Failure?

Lynn Doering - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Depression

ILS-969

Biomarkers for Prediction of Atrial Fibrillation in European Cohorts

Teemu Niiranen - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

Ergocalciferol

Elevated Inflammatory Plasma Biomarkers in Patients With Anderson-Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction

Brendan N Putko - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with preserved ejection fraction

ILS-969

The Clinical Significance of Diastolic Late Mitral Annular Velocity in Heart Failure With Preserved Left Ventricular Ejection Fraction

Eiichiro Yamamoto - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

A Lower Than Normal Aortic Diameter is a Prognostic Marker of Cardiac Events in Severe Dilated Cardiomyopathy

Tomohito Ohtani - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Dilated cardiomyopathy

N/A

Geriatric Nutritional Risk Index Predict Cardiovascular Events in Patients With Pheripheral Artery Disease

Takashi Miura - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Peripheral artery disease

N/A

The Incremental Value of Fourteen Novel Biomarkers for the Prediction of Cardiovascular Risk in Patients with Type 2 Diabetes

Joline W Beulens Jr - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

L-Tyrosine

The Clinical Impact of Eicosapentaenoic Acid/Arachidonic Acid Ratio in Adult Patients with Congenital Heart Disease

Kei Inai - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congenital heart disease

Icosapent ethyl

Plasma Levels of BNP are Lower in Patients with Heart failure with Preserved EF (HFpEF) as Compared with Those with Reduced EF (HFrEF)

Yuji Mizuno - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with preserved ejection fraction

N/A

Olmesartan Improves Not Only Vascular Endothelial Dysfunction but Cardiac Diastolic Dysfunction in Hypertensive Heart Failure with Preserved Ejection Fraction - ORION Study

Keisuke Ohba - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with preserved ejection fraction

Superoxide dismutase

Usefulness of B-type Natriuretic Peptide and High-sensitivity Cardiac Troponin for Risk Stratification in Low Flow, Low Gradient Aortic Stenosis -A Substudy of the TOPAS Study

Marie-Annick Clavel - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Preoperative Iodine-123 MIBG Scintigraphy Imaging as an Excellent Predictor of Left Ventricular Reverse Remodeling During Ventricular Assist Device Therapy

Koichiro Kinugawa - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Dilated cardiomyopathy

guanethidine

Myeloid Cell Derived Leucine Rich ?2 Glycoprotein Attenuates Adverse Cardiac Remodeling After Myocardial Infarction

Hiroyuki Nakayama - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

N/A

Impact of Modifiable Risk Factors on Circulating Concentrations of B-type Natriuretic Peptide and Cardiac Troponin T

Aruna D Pradhan - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Myocardial infarction

N/A

Impact of n-3 Polyunsaturated Fatty Acids on Mortality of Patients with Hospitalized Heart Failure Patients

Akiomi Yoshihisa - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

Icosapent ethyl

Clinically Feasible Electronic Health Record Tool for Stratification of 1- to 3-year Post-myocardial Infarction Risk of Cardiovascular Events: The Intermountain Acute Coronary Syndromes Risk Scores

Joseph B Muhlestein - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Post-myocardial infarction

Aspirin

Low Appendicular Skeletal Muscle Mass is Associated with High Coronary Plaque Complexity in Patients with ST-segment Elevation Myocardial Infarction

Eiichi Akiyama - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Myocardial infarction

TAXUS

Radiofrequency Ablation for Persistent Atrial Fibrillation: Earlier Catheter-based Interventions are Associated with Better Outcomes and in Direct Association with Markers of Pathways of Atrial Remodeling

Ayman A. Hussein - American Heart Association (AHA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

Filters

387 Abstracts